TY - JOUR
T1 - SCN5A Mutation Type and a Genetic Risk Score Associate Variably With Brugada Syndrome Phenotype in SCN5A Families
AU - Wijeyeratne, Yanushi D.
AU - Tanck, Michael W.
AU - Mizusawa, Yuka
AU - Batchvarov, Velislav
AU - Barc, Julien
AU - Crotti, Lia
AU - Bos, J. Martijn
AU - Tester, David J.
AU - Muir, Alison
AU - Veltmann, Christian
AU - Ohno, Seiko
AU - Page, Stephen P.
AU - Galvin, Joseph
AU - Tadros, Rafik
AU - Muggenthaler, Martina
AU - Raju, Hariharan
AU - Denjoy, Isabelle
AU - Schott, Jean Jacques
AU - Gourraud, Jean Baptiste
AU - Skoric-Milosavljevic, Doris
AU - Nannenberg, Eline A.
AU - Redon, Richard
AU - Papadakis, Michael
AU - Kyndt, Florence
AU - Dagradi, Federica
AU - Castelletti, Silvia
AU - Torchio, Margherita
AU - Meitinger, Thomas
AU - Lichtner, Peter
AU - Ishikawa, Taisuke
AU - Wilde, Arthur A.M.
AU - Takahashi, Kazuhiro
AU - Sharma, Sanjay
AU - Roden, Dan M.
AU - Borggrefe, Martin M.
AU - McKeown, Pascal P.
AU - Shimizu, Wataru
AU - Horie, Minoru
AU - Makita, Naomasa
AU - Aiba, Takeshi
AU - Ackerman, Michael J.
AU - Schwartz, Peter J.
AU - Probst, Vincent
AU - Bezzina, Connie R.
AU - Behr, Elijah R.
N1 - Publisher Copyright:
© 2020 Lippincott Williams and Wilkins. All rights reserved.
PY - 2020/12/1
Y1 - 2020/12/1
N2 - Background: Brugada syndrome (BrS) is characterized by the type 1 Brugada ECG pattern. Pathogenic rare variants in SCN5A (mutations) are identified in 20% of BrS families in whom incomplete penetrance and genotype-negative phenotype-positive individuals are observed. E1784K-SCN5A is the most common SCN5A mutation identified. We determined the association of a BrS genetic risk score (BrS-GRS) and SCN5A mutation type on BrS phenotype in BrS families with SCN5A mutations. Methods: Subjects with a spontaneous type 1 pattern or positive/negative drug challenge from cohorts harboring SCN5A mutations were recruited from 16 centers (n=312). Single nucleotide polymorphisms previously associated with BrS at genome-wide significance were studied in both cohorts: rs11708996, rs10428132, and rs9388451. An additive linear genetic model for the BrS-GRS was assumed (6 single nucleotide polymorphism risk alleles). Results: In the total population (n=312), BrS-GRS ≥4 risk alleles yielded an odds ratio of 4.15 for BrS phenotype ([95% CI, 1.45-11.85]; P=0.0078). Among SCN5A-positive individuals (n=258), BrS-GRS ≥4 risk alleles yielded an odds ratio of 2.35 ([95% CI, 0.89-6.22]; P=0.0846). In SCN5A-negative relatives (n=54), BrS-GRS ≥4 alleles yielded an odds ratio of 22.29 ([95% CI, 1.84-269.30]; P=0.0146). Among E1784K-SCN5A positive family members (n=79), hosting ≥4 risk alleles gave an odds ratio=5.12 ([95% CI, 1.93-13.62]; P=0.0011). Conclusions: Common genetic variation is associated with variable expressivity of BrS phenotype in SCN5A families, explaining in part incomplete penetrance and genotype-negative phenotype-positive individuals. SCN5A mutation genotype and a BrS-GRS associate with BrS phenotype, but the strength of association varies according to presence of a SCN5A mutation and severity of loss of function.
AB - Background: Brugada syndrome (BrS) is characterized by the type 1 Brugada ECG pattern. Pathogenic rare variants in SCN5A (mutations) are identified in 20% of BrS families in whom incomplete penetrance and genotype-negative phenotype-positive individuals are observed. E1784K-SCN5A is the most common SCN5A mutation identified. We determined the association of a BrS genetic risk score (BrS-GRS) and SCN5A mutation type on BrS phenotype in BrS families with SCN5A mutations. Methods: Subjects with a spontaneous type 1 pattern or positive/negative drug challenge from cohorts harboring SCN5A mutations were recruited from 16 centers (n=312). Single nucleotide polymorphisms previously associated with BrS at genome-wide significance were studied in both cohorts: rs11708996, rs10428132, and rs9388451. An additive linear genetic model for the BrS-GRS was assumed (6 single nucleotide polymorphism risk alleles). Results: In the total population (n=312), BrS-GRS ≥4 risk alleles yielded an odds ratio of 4.15 for BrS phenotype ([95% CI, 1.45-11.85]; P=0.0078). Among SCN5A-positive individuals (n=258), BrS-GRS ≥4 risk alleles yielded an odds ratio of 2.35 ([95% CI, 0.89-6.22]; P=0.0846). In SCN5A-negative relatives (n=54), BrS-GRS ≥4 alleles yielded an odds ratio of 22.29 ([95% CI, 1.84-269.30]; P=0.0146). Among E1784K-SCN5A positive family members (n=79), hosting ≥4 risk alleles gave an odds ratio=5.12 ([95% CI, 1.93-13.62]; P=0.0011). Conclusions: Common genetic variation is associated with variable expressivity of BrS phenotype in SCN5A families, explaining in part incomplete penetrance and genotype-negative phenotype-positive individuals. SCN5A mutation genotype and a BrS-GRS associate with BrS phenotype, but the strength of association varies according to presence of a SCN5A mutation and severity of loss of function.
KW - Brugada syndrome
KW - genetics, human
KW - penetrance
KW - phenotype
KW - risk score
UR - http://www.scopus.com/inward/record.url?scp=85097964476&partnerID=8YFLogxK
U2 - 10.1161/CIRCGEN.120.002911
DO - 10.1161/CIRCGEN.120.002911
M3 - Article
C2 - 33164571
AN - SCOPUS:85097964476
SN - 2574-8300
VL - 13
SP - E002911
JO - Circulation. Genomic and precision medicine
JF - Circulation. Genomic and precision medicine
IS - 6
ER -